ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
ChromaDex Corp. (NASDAQ:CDXC) has announced the nationwide rollout of its Niagen® IV products at over 200 Restore Hyper Wellness locations across the United States. Niagen IV, a pharmaceutical-grade nicotinamide riboside chloride (NRC) product, represents an advancement in NAD+ therapy, offering superior benefits compared to traditional NAD+ IV treatments. In clinical studies, Niagen IV demonstrated a 75% shorter infusion time, better tolerability, and achieved a 20% increase in whole blood NAD+ levels three hours post-infusion. The product is compounded and distributed by Wells Pharma of Houston, an FDA-registered 503B facility, and is available exclusively for clinics with medical clearance.
ChromaDex Corp. (NASDAQ:CDXC) ha annunciato il lancio a livello nazionale dei suoi prodotti Niagen® IV in oltre 200 punti Restore Hyper Wellness in tutto il territorio degli Stati Uniti. Niagen IV, un prodotto a base di cloruro di nicotinamide riboside (NRC) di grado farmaceutico, rappresenta un avanzamento nella terapia NAD+, offrendo benefici superiori rispetto ai tradizionali trattamenti IV NAD+. Negli studi clinici, Niagen IV ha dimostrato un tempo di infusione più breve del 75%, una migliore tollerabilità e ha raggiunto un aumento del 20% dei livelli di NAD+ nel sangue intero tre ore dopo l'infusione. Il prodotto è preparato e distribuito da Wells Pharma di Houston, un impianto registrato FDA 503B, ed è disponibile esclusivamente per cliniche con approvazione medica.
ChromaDex Corp. (NASDAQ:CDXC) ha anunciado el lanzamiento a nivel nacional de sus productos Niagen® IV en más de 200 ubicaciones de Restore Hyper Wellness en Estados Unidos. Niagen IV, un producto de cloruro de nicotinamida ribósido (NRC) de grado farmacéutico, representa un avance en la terapia NAD+, ofreciendo beneficios superiores en comparación con los tratamientos IV de NAD+ tradicionales. En estudios clínicos, Niagen IV demostró un tiempo de infusión un 75% más corto, mejor tolerancia y logró un aumento del 20% en los niveles de NAD+ en sangre total tres horas después de la infusión. El producto es compuesto y distribuido por Wells Pharma de Houston, una instalación 503B registrada en la FDA, y está disponible exclusivamente para clínicas con autorización médica.
ChromaDex Corp. (NASDAQ:CDXC)는 미국 전역의 200개 이상의 Restore Hyper Wellness 위치에서 Niagen® IV 제품의 전국 배포를 발표했습니다. Niagen IV는 제약 등급인 니코티나마이드 리보사이드 클로라이드(NRC) 제품으로, NAD+ 치료에서의 발전을 나타내며 전통적인 NAD+ IV 치료법에 비해 우수한 이점을 제공합니다. 임상 연구에서 Niagen IV는 75% 짧은 주입 시간, 더 나은 내약성, 그리고 주입 후 3시간에 전체 혈액 NAD+ 수치가 20% 증가하는 것을 증명했습니다. 이 제품은 FDA에 등록된 503B 시설인 Houston의 Wells Pharma에서 조제 및 배포되며, 의학적 승인된 클리닉에 한정하여 제공됩니다.
ChromaDex Corp. (NASDAQ:CDXC) a annoncé le déploiement national de ses produits Niagen® IV dans plus de 200 établissements Restore Hyper Wellness à travers les États-Unis. Niagen IV, un produit à base de chlorure de nicotinamide riboside (NRC) de qualité pharmaceutique, représente une avancée dans le traitement NAD+, offrant des avantages supérieurs par rapport aux traitements IV NAD+ traditionnels. Dans des études cliniques, Niagen IV a montré un temps d'infusion 75% plus court, une meilleure tolérabilité et a atteint une augmentation de 20% des niveaux de NAD+ dans le sang total trois heures après l'infusion. Le produit est composé et distribué par Wells Pharma à Houston, un établissement 503B enregistré auprès de la FDA, et est disponible exclusivement pour les cliniques avec autorisation médicale.
ChromaDex Corp. (NASDAQ:CDXC) hat die landesweite Einführung seiner Niagen® IV Produkte in über 200 Restore Hyper Wellness Standorten in den Vereinigten Staaten angekündigt. Niagen IV, ein Produkt aus pharmazeutischem nicotinamide riboside chloride (NRC), stellt einen Fortschritt in der NAD+ Therapie dar und bietet im Vergleich zu herkömmlichen NAD+ IV Behandlungen überlegene Vorteile. In klinischen Studien zeigte Niagen IV eine 75% kürzere Infusionszeit, eine bessere Verträglichkeit und erreichte eine Steigerung von 20% der NAD+ Spiegel im Vollblut drei Stunden nach der Infusion. Das Produkt wird von Wells Pharma in Houston, einer FDA-registrierten 503B Einrichtung, zusammengesetzt und verteilt und ist ausschließlich für Kliniken mit medizinischer Genehmigung erhältlich.
- Expanded distribution to over 200 wellness clinics nationwide
- Clinical data shows 75% shorter infusion time compared to traditional NAD+ IV
- Demonstrated 20% increase in whole blood NAD+ levels in clinical studies
- Superior tolerability compared to traditional NAD+ IV therapy
- None.
Insights
The nationwide rollout of Niagen IV through Restore Hyper Wellness represents a significant commercial expansion for ChromaDex's pharmaceutical-grade NAD+ therapy. The clinical data showing
The partnership with a FDA-registered 503B facility adds credibility and ensures pharmaceutical-grade quality, while the clinical validation through pilot studies strengthens the product's market position. The superior tolerability and efficiency profile could drive stronger adoption in the competitive IV therapy space, potentially leading to increased market share and revenue growth for ChromaDex.
National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy
Available in oral and IV forms, ChromaDex’s clinically proven patented ingredient, Niagen, is the most efficient, high-quality NAD+ precursor available. NAD+ is a coenzyme that powers cells and supports metabolic processes throughout the body, yet it declines with age and due to everyday stressors like sun exposure, high-fat diets, overtraining, and sedentary lifestyles—a decline linked to both age-related and other health conditions.
The IV formulations support the rapid and efficient delivery of Niagen. Outperforming NAD+ IV in the pilot clinical study, Niagen IV offered superior tolerability, a
“Niagen IV is a superior solution to traditional NAD+ IV,” said Rob Fried, CEO of ChromaDex. “We are pleased that reliably science based Restore Hyper Wellness recognizes these advantages and is offering Niagen IV nationwide.”
Restore Hyper Wellness, known for its innovative approach to proactive health and wellness, provides access to advanced modalities, with safety and efficacy as core principles. Restore’s extensive network of clinics offers clients a holistic experience designed to address their wellness goals and optimize physical health.
“We’ve seen firsthand how Niagen IV elevates the wellness experience for our clients, delivering enhanced cellular support compared to NAD+ IV,” said Dr. Rachele Pojednic, Director of Scientific Research & Education at Restore Hyper Wellness. “Pharmaceutical-grade Niagen provides a cutting-edge option that reflects our commitment to impactful, science-driven care.”
To learn more about Niagen IV at Restore Hyper Wellness, visit www.restore.com. Consumers can visit www.niagenplus.com to sign up for product news and updates on future clinic availability and use the store locator to find a clinic offering Niagen IV near you.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to future increased availability of pharmaceutical grade Niagen, and future performance of pharmaceutical grade Niagen. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ: CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen ® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen ®, the number one healthy-aging NAD+ supplement in
ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.
† Based on the top-selling dietary supplement brands by revenue per the largest
About Restore Hyper Wellness:
Launched in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107717521/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
What are the clinical benefits of ChromaDex's Niagen IV (CDXC) compared to traditional NAD+ therapy?
How many locations now offer ChromaDex's Niagen IV (CDXC) treatment?
Where is ChromaDex's Niagen IV (CDXC) manufactured and distributed?
